Hereditary Hemorrhagic Telangiectasia (HHT): Understanding a Rare but Manageable Condition
Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler–Weber–Rendu syndrome, is a rare genetic disorder that affects blood vessels and leads to abnormal connections between arteries and veins. These malformed vessels, known as telangiectasias and arteriovenous malformations (AVMs), can appear throughout the body and may cause significant health challenges if not properly managed. Although HHT is inherited, many people remain undiagnosed for years because its symptoms vary widely in severity and may resemble other conditions. Understanding the nature of the disease, its symptoms, and the importance of early detection can make a profound difference in long-term health outcomes.
One of the most recognizable signs of HHT is frequent nosebleeds, often beginning in childhood or adolescence. These nosebleeds occur due to delicate and irregular blood vessels in the nasal passages that are prone to breaking. While occasional bleeding may be dismissed as harmless, recurring episodes are a key indicator that further evaluation is needed. As individuals grow older, small red or purple spots, known as telangiectasias, may appear on the lips, tongue, face, or hands. These spots represent clusters of fragile blood vessels close to the surface of the skin.
Beyond these visible features, HHT can affect internal organs, which is where serious complications may arise. AVMs can develop in vital areas such as the lungs, brain, liver, gastrointestinal tract, and spine. In the lungs, AVMs may allow unfiltered blood to circulate, increasing the risk of stroke or brain abscess. Brain AVMs, although less common, can lead to seizures or bleeding if left undetected. Liver involvement may cause high-output heart failure in severe cases. Despite these possibilities, many individuals with HHT live normal lives with proper monitoring and care.
Because HHT is genetic, a family history of similar symptoms is often an important clue. The condition follows an autosomal dominant pattern, meaning a child has a 50% chance of inheriting the disorder if one parent carries the gene mutation. Genetic testing can confirm the diagnosis, but clinical evaluation remains equally important, especially in areas where testing is limited or unavailable. Doctors may use imaging techniques such as MRI, CT scans, or ultrasound to check for AVMs in organs that may not show obvious symptoms.
Managing HHT typically involves addressing symptoms and monitoring for complications. Nosebleeds can often be controlled through humidification, topical treatments, or laser therapy to reduce fragile blood vessels. Iron supplements or, in some cases, blood transfusions may be needed for individuals with significant blood loss. AVMs in the lungs or brain may be treated with minimally invasive procedures such as embolization, which helps block abnormal blood flow. Regular follow-ups with specialists ensure that any changes in the condition are detected early.